Joanna Glasner Contributor More posts by this contributor Big revenues, huge valuations and major losses: charting the era of the unicorn IPO Some reassuring data for...
Joanna Glasner Contributor More posts by this contributor A record $2.5B went to US insurance startup deals last year, and big insurers are in all the...
Joanna Glasner Contributor More posts by this contributor From lab-grown meat to fermented fungus, here’s what corporate food VCs are serving up Space tech rockets higher...
Joanna Glasner Contributor More posts by this contributor Where seed and early-stage funding is growing, contracting or holding steady Hire faster, work happier: Startups target employment...
Joanna Glasner Contributor More posts by this contributor Robot couriers scoop up early-stage cash Bots replacing office workers drive big valuations If you have a job...
Joanna Glasner Contributor More posts by this contributor Home run exits happen stealthily for biotech While tech waffles on going public, biotech IPOs boom Boston has...
For people who make investment decisions based on revenues and projected earnings, biotech IPOs are kind of a non-starter. Not only are new market entrants universally...
